<DOC>
	<DOCNO>NCT02133469</DOCNO>
	<brief_summary>A parallel-group , randomize , open-label study perform subject receive PCV7 subject receive control vaccine Hib vaccine , claim efficacy PCV7 prevention NP carriage vaccine-serotype S. pneumoniae ( serotypes 4 , 6B , 9V , 14 , 18C , 19F , 23F combine ) 2 5 year old healthy Chinese child .</brief_summary>
	<brief_title>PCV7 Prevention Nasopharyngeal Carriage Vaccine Serotype ( VT ) Streptococcus Pneumoniae</brief_title>
	<detailed_description>In 2005 , clinical trial PCV7 ( Prevenar ) first conduct China . In phase 3 study involve Chinese infant , Prevenar show immunogenic , well tolerate , safe give either separately concomitantly diphtheria , tetanus , acellular pertussis ( DTaP ) vaccine 3 , 4 , 5 month age . Controlled clinical trial elsewhere world show correlation immunogenicity disease prevention . In addition direct effect Prevenar , immunization child also reduce incidence disease adult . The change presume due reduction nasopharyngeal carriage vaccine serotype S. pneumoniae child vaccinate . The purpose study assess effectiveness Prevenar vaccination reduce vaccine serotype ( VT ) NPC rate Chinese child age 2 5 year old .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumococcal</mesh_term>
	<mesh_term>Nasopharyngeal Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1 . Healthy child age 2 5 year . 2 . Evidence personally sign date informed consent document indicate parent ( ) ( legal guardian ) inform pertinent aspect study . 3 . Subjects parent / legal guardian/ adult caregiver willing able comply schedule visit , treatment plan , study procedure . 4 . Available entire study period whose parent/legal guardian/adult caregiver reach telephone . 5 . Healthy child determine medical history , physical examination , judgment investigator . 1 . Previous vaccination license investigational pneumococcal vaccine . 2 . Receipt full series catchup dose license investigational Hib vaccination . 3 . Contraindication vaccination pneumococcal conjugate vaccine Hib . 4 . Bleeding diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection . 5 . Known suspected immune deficiency suppression include treatment systemic steroid , antimetabolite , chemotherapy immunomodulatory agent . 6 . Major know congenital malformation serious chronic disorder . 7 . Malformation injury nasopharynx make procedure take nasopharyngeal swab impossible . 8 . Significant neurologic disorder include congenital neurological disease sibling subject history seizure include febrile seizure , significant stable evolve disorder cerebral palsy , encephalopathy , hydrocephalus , significant disorder . Does include resolve syndrome due birth trauma Erb 's palsy . 9 . Receipt blood product gammaglobulin ( include hepatitis B immunoglobulin monoclonal antibody ) within 12 week prior enrollment . 10 . Participation another investigational interventional trial within 28day period enrollment conduct study . Participation purely observational study acceptable . 11 . Subjects whose parent legal representative investigational site staff member subject whose parent legal representative Pfizer employee directly involve conduct trial . Temporary Exclusion Criteria ( The follow condition temporary selflimiting subject may include study condition ( ) has/have resolve exclusion criterion meet ) : 1 . Subjects current febrile illness ( axillary temperature ≥ 38.0ºC ) . 2 . Subjects use antibiotic within previous 15 day .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Effectiveness</keyword>
	<keyword>Prevenar</keyword>
	<keyword>nasopharyngeal carriage</keyword>
	<keyword>vaccine serotype</keyword>
</DOC>